Drug is used to treat osteoporosis and menopausal symptoms, but study found that it might increase BC recurrence sharply.
Unfortunately, this Lancet Oncology article does not seem to be available in full text, but the study was cancelled early to prevent harm to patients and an accompanying editorial is called Tibolone: The Risk is Too High.